AcquisitionOther
Aptose Biosciences Inc. acquired target
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Aptose Biosciences Inc. -> target · $2.41
The Company’s small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
Open source record (SEC) ↗